RxDoctor Payments DataLook up a doctor →

Darrick Neibaur, DO

Ophthalmology · Henderson, NVNPI 1134375918

Payments from drug & device makers

$35,748in general payments, 2019–2025

Across 448 payments — averaging $79.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$14K
  • Alcon$3K
  • AbbVie$3K
  • Bausch & Lomb Americas Inc.$2K
  • Ivantis, Inc$2K
  • Novartis$1K
  • plus $10K from 29 others

What the payments were for

  • Consulting fees$2,5537%
  • Speaking & faculty fees$11,02831%
  • Travel & lodging$3,74810%
  • Food & beverage$17,67949%
  • Education$800%
  • Other$6602%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,748 in reported general payments places this provider in the 80th percentile of 121 ophthalmology providers in Nevada.

See all ophthalmology providers in Nevada

Medicare billing

Part B allowed, 2024
$373,844
Medicare patients
837
Services billed
2,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine205$282,567
IlevroNepafenac232$85,049
LumiganBimatoprost121$58,375
XiidraLifitegrast33$51,152
Prednisolone Acetate1,227$41,630
RocklatanNetarsudil Mesylat/Latanoprost40$30,646
ProlensaBromfenac Sodium80$27,952
CombiganBrimonidine Tartrate/Timolol74$25,707
TyrvayaVarenicline Tartrate27$17,623
Lotemax SmLoteprednol Etabonate46$14,263
Cyclosporine21$11,666
SimbrinzaBrinzolamide/Brimonidine Tart36$10,941
Alphagan PBrimonidine Tartrate19$9,336
Ofloxacin753$9,098
Bromfenac Sodium46$8,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$2,728$375,985419 claims
NovartisIlevro$1,416$85,049232 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$2,230$56,56747 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm$713$42,216126 claims
Aerie Pharmaceuticals, Inc.Rocklatan$315$30,64640 claims
Oyster Point Pharma, Inc.Tyrvaya$376$17,62327 claims
AlconSimbrinza$3,252$10,94136 claims
Sun Pharmaceutical Industries Inc.Bromsite$14,293$6,52625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 121 ophthalmology providers in Nevada.

Other ophthalmology in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →